Helicobacter Pylori Eradication and Irritable Bowel Syndrome: A Prospective Study

Phase 4

• Conditions: Irritable Bowel Syndrome
• Interventions: Drug: Triple therapy for H.pylori

• Registration Number: NCT04512898
• Lead Sponsor: Assiut University

Brief Summary

H. Pylori is frequently observed in patients with irritable bowel syndrome(IBS). However, the effect of H. pylori eradication on IBS is not clear.

Detailed Description

Patients with IBS symptoms using Rome IV criteria will be included. Testing for H. pylori will be done. Patients with H. pylori will receive triple therapy and followed after two weeks for eradication and assessment of IBS symptoms.

Study Timeline

• Status Verified: 2020-08
• Study First Submitted: 2020-08-03
• Study Start: 2020-08-10
• Study First Submitted QC: 2020-08-11
• Last Update Submitted: 2020-08-11
• Study First Posted: 2020-08-14
• Last Update Posted: 2020-08-14
• Primary Completion: 2020-11-10
• Study Completion: 2020-11-10

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• Patients newly diagnosed with IBS and H.pylori

Exclusion Criteria

• Patients received previous treatment of H.pylori
• Patients receiving treatment for IBS.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Patient with IBS	Triple therapy for H.pylori	Patients with IBS and positive H. pylori.

Primary Outcome Measures

Name	Time	Method
Questionnaire for Rome IV criteria	2 weeks	Symptoms of IBS

Secondary Outcome Measures

Name	Time	Method
Quality of life questionnaire	2 weeks	Quality of life.